Loading...

ACAD ACADIA PHARMACEUTICALS INC Disposals and divestitures 8-K Filing

CD P

CD

ACADIA PHARMACEUTICALS INC

(ACAD)

2024 8-K

Show Summary

Show Summary

Management Changes

Earnings Releases

Bylaw Amendments

Financial Results

Management Change

Q3 Financial Results

Financial Results Announcement

Annual Meeting Approval

Financial Results Announcement

Results of Phase 3 ADVANCE-...

Financial Results Announcement

Departure of Directors

Management Change

Financial Results Announcement

Financial Results Announcement

Financial Results Announcement

Financial Results Announcement

External Links:

Acadia Pharmaceuticals completed the sale of its Rare Pediatric Disease Priority Review Voucher for $150 million, with one third of the proceeds going to Neuren Pharmaceuticals as per their agreement.

AI Assistant

ACADIA PHARMACEUTICALS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.